Trials / Completed
CompletedNCT02626884
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine 1. Disease stabilization/response rate after six 21-day cycles of ibrutinib 2. Remission status after six, twelve and 20 21-day cycles of ibrutinib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibrutinib |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2020-08-01
- Completion
- 2020-08-01
- First posted
- 2015-12-10
- Last updated
- 2021-04-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02626884. Inclusion in this directory is not an endorsement.